FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma

Regulatory Approvals — FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma  Oncology Nursing News

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. September 23, 2026.

By